Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
23.19
+0.01 (0.04%)
At close: Oct 16, 2026, 4:00 PM EDT
23.18
-0.01 (-0.04%)
After-hours: Oct 16, 2026, 7:32 PM EDT
Collegium Pharmaceutical Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Collegium Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $49. The average 1-year stock price forecast is 111.30% higher than the current stock price, while the lowest is $43 (+85.42%) and the highest is $60 (+158.73%).
Price Target: $49 (+111.30%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Collegium Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 5 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 5 | 5 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $48 | Buy | Maintains | $48 | +106.99% | Oct 15, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $50 | Buy | Reiterates | $50 | +115.61% | Oct 9, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $60 | Buy | Maintains | $60 | +158.73% | Sep 21, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $45 | Buy | Initiates | $45 | +94.05% | Sep 9, 2026 |
| Truist Financial No rating | Truist Financial | Buy Initiates $58 → $49 | Buy | Initiates | $58 → $49 | +111.30% | Sep 9, 2026 |
Financial Forecast
Revenue This Year
833.11M
from 780.57M
Increased by 6.73%
Revenue Next Year
844.53M
from 833.11M
Increased by 1.37%
EPS This Year
7.46
from 7.42
Increased by 0.52%
EPS Next Year
7.26
from 7.46
Decreased by -2.69%
EPS and Forward PE are based on non-GAAP adjusted numbers.